menu search

Vyne therapeutics' bet inhibitor shows encouraging preclinical action in skin disorder

VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic autoimmune depigmenting disor...

March 7, 2022, 12:06 pm


Search within

Pages Search Results: